Article: Nicotinamide Riboside Prevents Hearing Loss in Cockayne Syndrome: Preclinical Findings

PrevNext
Cardiovascular Disease Cardiovascular Health Preclinical

Nicotinamide Riboside Prevents Hearing Loss in Cockayne Syndrome: Preclinical Findings

Synopsis

Age-related hearing loss (ARHL) is one of the most common disorders affecting elderly individuals. There is an urgent need for effective preventive measures for ARHL because none are currently available. Cockayne syndrome (CS), a premature aging disease, causes early hearing loss similar to age-related hearing loss. Using mouse models of CS, researchers found that NAD+ levels drop in the cochlea. Short-term treatment with nicotinamide riboside (NR), an NAD+ precursor, prevented hearing loss, restored outer hair cells, and improved cochlear health. NR also reversed deficits in synaptic ribbons crucial for hearing, likely by supporting the NAD(H)-dependent protein Ribeye. These results point to NR as a potential treatment for hearing loss in CS and aging.

Journal

npj Aging and Mechanisms of Disease

Share

Read more

Amyotrophic Lateral Sclerosis (ALS)

Nicotinamide Riboside Supports Mitochondrial Health and Neurogenesis in ALS: Preclinical Findings

Synopsis Amyotrophic lateral sclerosis (ALS) is a disease where motor neurons progressively degenerate, leading to muscle weakness and paralysis. Declines in NAD+ contribute to mitochondrial dysfu...

Read more
Cardiovascular Disease

Nicotinamide Riboside Protects the Brain from Hypertension-Related Small Vessel Damage: Preclinical Findings

Synopsis Hypertension can cause damage to small blood vessels in the brain, leading to memory problems and white matter injury, but treatments are limited. In this study, mice with angiotensin-ind...

Read more